Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate.
Schoch
C
C
Haferlach
T
T
Kern
W
W
Schnittger
S
S
Berger
U
U
Hehlmann
R
R
Hiddemann
W
W
Hochhaus
A
A
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001549:Benzamides; D002869:Chromosome Aberrations; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use*; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate